Isobolographic analysis of pharmacodynamic interactions between antifungal agents and ciprofloxacin against Candida albicans and Aspergillus fumigatus.
Anti-Bacterial Agents/metabolism/pharmacology; Antifungal Agents/metabolism/pharmacology; Aspergillus fumigatus/drug effects/growth & development; Candida albicans/drug effects/growth & development; Ciprofloxacin/metabolism/pharmacology; Dose-Response Relationship, Drug; Drug Antagonism; Drug Interactions; Drug Synergism; Humans; Microbial Sensitivity Tests/methods; Regression Analysis
Abstract :
[en] Patients suffering from invasive mycoses often receive concomitant antifungal therapy and antibacterial agents. Assessment of pharmacodynamic interactions between antifungal and antibacterial agents is complicated by the absence of a common antifungal end point for both agents. Ciprofloxacin has no intrinsic antifungal activity but may interact with antifungal agents, since it inhibits DNA gyrase (topoisomerase II), which is abundant in fungi. We therefore employed isobolographic analysis adapted to incorporate a nonactive agent in order to analyze the potential in vitro interaction between the fluoroquinolone ciprofloxacin and several representative antifungal agents against Candida albicans and Aspergillus fumigatus strains by using a microdilution checkerboard technique. In agreement with earlier in vitro studies, conventional fractional inhibitory concentration index analysis was unable to detect interactions between ciprofloxacin and antifungal agents. However, isobolographic analysis revealed significant pharmacodynamic interactions between antifungal agents and ciprofloxacin against C. albicans and A. fumigatus strains. Amphotericin B demonstrated concentration-dependent interactions for both species, with synergy (interaction indices, 0.14 to 0.81) observed at ciprofloxacin concentrations of <10.64 microg/ml. Synergy (interaction indices, 0.10 to 0.86) was also found for voriconazole and caspofungin against A. fumigatus. Isobolographic analysis may help to elucidate the pharmacodynamic interactions between antifungal and non-antifungal agents and to develop better management strategies against invasive candidiasis and aspergillosis.
Isobolographic analysis of pharmacodynamic interactions between antifungal agents and ciprofloxacin against Candida albicans and Aspergillus fumigatus.
Publication date :
2008
Journal title :
Antimicrobial Agents and Chemotherapy
ISSN :
0066-4804
eISSN :
1098-6596
Publisher :
American Society for Microbiology, United States - District of Columbia
American Society for Microbiology. 2007. Instructions to authors. Antimicrob. Agents Chemother. 51:1-22.
Antoniadou, A., and H. Giamarellou. 2007. Fever of unknown origin in febrile leukopenia. Infect. Dis. Clin. N. Am. 21:1055-1090.
Berenbaum, M. C. 1989. What is synergy? Pharmacol. Rev. 41:93-141.
Borowicz, K. K., M. Swiader, J. Luszezki, and S. J. Czuczwar. 2002. Effect of gabapentin on the anticonvulsant activity of antiepileptic drugs against electroconvulsions in mice: an isobolographic analysis. Epilepsia 43:956-963.
Faessel, H. M., L. M. Levasseur, H. K. Slocum, and W. R. Greco. 1999. Parabolic growth patterns in 96-well plate cell growth experiments. In Vitro Cell. Dev. Biol. Anim. 35:270-278.
Fostel, J. M., D. A. Montgomery, and L. L. Shen. 1992. Characterization of DNA topoisomerase I from Candida albicans as a target for drug discovery. Antimicrob. Agents Chemother. 36:2131-2138.
Johnson, M. D., C. MacDougall, L. Ostrosky-Zeichner, J. R. Perfect, and J. H. Rex. 2004. Combination antifungal therapy. Antimicrob. Agents Chemother. 48:693-715.
Levasseur, L. M., W. R. Greco, Y. M. Rustum, and H. K. Slocum. 1997. Combined action of paclitaxel and cisplatin against wildtype and resistant human ovarian carcinoma cells. Cancer Chemother. Pharmacol. 40:495-505.
Luszezki, J. J., M. Czuczwar, J. Kis, J. Krysa, I. Pasztelan, M. Swiader, and S. J. Czuczwar. 2003. Interactions of lamotrigine with topiramate and first-generation antiepileptic drugs in the maximal electroshock test in mice: an isobolographic analysis. Epilepsia 44:1003-1013.
Luszczki, J. J., and S. J. Czuczwar. 2006. Gabapentin synergisrically interacts with topiramate in the mouse maximal electroshock seizure model: an isobolographic analysis. Pharmacol. Rep. 58:944-954.
Maurer, N., K. F. Wong, M. J. Hope, and P. R. Cullis. 1998. Anomalous solubility behavior of the antibiotic ciprofloxacin encapsulated in liposomes: a 1H-NMR study. Biochim. Biophys. Acta 1374:9-20.
Meletiadis, J., V. Petraitis, R. Petraitiene, P. Lin, T. Stergiopoulou, A. M. Kelaher, T. Sein, R. L. Schaufele, J. Bacher, and T. J. Walsh. 2006. Triazole-polyene antagonism in experimental invasive pulmonary aspergillosis: in vitro and in vivo correlation. J. Infect. Dis. 194:1008-1018.
Meletiadis, J., T. Stergiopoulou, E. M. O'Shaughnessy, J. Peter, and T. J. Walsh. 2007. Concentration-dependent synergy and antagonism within a triple antifungal drug combination against Aspergillus species: analysis by a new response surface model. Antimicrob. Agents Chemother. 51:2053-2064.
Meletiadis, J., D. T. Te Dorsthorst, and P. E. Verweij. 2006. The concentration-dependent nature of in vitro amphotericin B-itraconazole interaction against Aspergillus fumigatus: isobolographic and response surface analysis of complex pharmacodynamic interactions. Int. J. Antimicrob. Agents 28:439-449.
Michot, J. M., F. Van Bambeke, M. P. Mingeot-Leclercq, and P. M. Tulkens. 2004. Active efflux of ciprofloxacin from J774 macrophages through an MRP-like transporter. Antimicrob. Agents Chemother. 48:2673-2682.
Mimoz, O., V. Binter, A. Jacolot, A. Edouard, M. Tod, O. Petitjean, and K. Samii. 1998. Pharmacokinetics and absolute bioavailability of ciprofloxacin administered through a nasogastric tube with continuous enteral feeding to critically ill patients. Intensive Care Med. 24:1047-1051.
Miranda, H. F., E. Silva, and G. Pinardi. 2004. Synergy between the antinociceptive effects of morphine and NSAIDs. Can. J. Physiol. Pharmacol. 82:331-338.
Motulsky, H. C., and A. Christopoulos. 2003. Fitting models to biological data using linear and nonlinear regression. A practical guide to curve fitting. GraphPad Software, Inc., San Diego, CA.
Nakajima, R., A. Kitamura, K. Someya, M. Tanaka, and K. Sato. 1995. In vitro and in vivo antifungal activities of DU-6859a, a fluoroquinolone, in combination with amphotericin B and fluconazole against pathogenic fungi. Antimicrob. Agents Chemother. 39:1517-1521.
NCCLS. 2002. Reference method for broth dilution antifungal susceptibility testing of filamentous fungi; approved standard. M38-A, vol. 22, no 16. NCCLS, Wayne, PA.
Nosari, A., P. Oreste, R. Cairoli, M. Montillo, G. Carrafiello, A. Astolfi, G. Muti, L. Marbello, A. Tedeschi, E. Magliano, and E. Morra. 2001. Invasive aspergillosis in haematological malignancies: clinical findings and management for intensive chemotherapy completion. Am. J. Hematol. 68:231-236.
Otsu, Y., K. Yanagihara, Y. Fukuda, Y. Miyazaki, K. Tsukamoto, Y. Hirakata, K. Tomono, J. Kadota, T. Tashiro, I. Murata, and S. Kohno. 2003. In vivo efficacy of a new quinolone, DQ-113, against Streptococcus pneumoniae in a mouse model. Antimicrob. Agents Chemother. 47:3699-3703.
Overbeek, B. P., M. Rozenberg-Arska, and J. Verhoef. 1985. Do quinolones really augment the antifungal effect of amphotericin B in vitro? Drugs Exp. Clin. Res. 11:745-746.
Perea, S., and T. F. Patterson. 2002. Invasive Aspergillus infections in hematologic malignancy patients. Semin. Respir. Infect. 17:99-105.
Perez-Vizcaino, F., A. L. Cogolludo, F. Zaragoza-Arnaez, S. Fajardo, M. Ibarra, J. G. Lopez-Lopez, and J. Tamargo. 1999. Vasodilator effects of sodium nitroprusside, levcromakalim and their combination in isolated rat aorta. Br. J. Pharmacol. 128:1419-1426.
Petrou, M. A., and T. R. Rogers. 1988. In-vitro activity of antifungal agents in combination with four quinolones. Drugs Exp. Clin. Res. 14:9-18.
Polak, A. 1990. In vitro and in vivo activity of antifungal agents in combination with fleroxacin, a new quinolone. Mycoses 33:173-178.
Sasaki, E., S. Maesaki, Y. Miyazaki, K. Yanagihara, K. Tomono, T. Tashiro, and S. Kohno. 2000. Synergistic effect of ofloxacin and fluconazole against azole-resistant Candida albicans. J. Infect. Chemother. 6:151-154.
Satyanarayana, P. S., N. K. Jain, A. Singh, and S. K. Kulkarni. 2004. Isobolographic analysis of interaction between cyclooxygenase inhibitors and tramadol in acetic acid-induced writhing in mice. Prog. Neuropsychopharmacol. Biol. Psychiatry 28:641-649.
Schuetzer-Muehlbauer, M., B. Willinger, G. Krapf, S. Enzinger, E. Presterl, and K. Kuchler. 2003. The Candida albicans Cdr2p ATP-binding cassette (ABC) transporter confers resistance to caspofungin. Mol. Microbiol. 48:225-235.
Shalit, I., D. Halperin, D. Haite, A. Levitov, J. Romano, N. Osherov, and I. Fabian. 2006. Anti-inflammatory effects of moxifloxacin on IL-8, IL-Iβ and TNF-α secretion and NF-κB and MAP-kinase activation in human monocytes stimulated with Aspergillus fumigatus. J. Antimicrob. Chemother. 57:230-235.
Shalit, I., L. Horev-Azaria, I. Fabian, H. Blau, N. Kariv, I. Shechtman, H. Alteraz, and Y. Kletter. 2002. Immunomodulatory and protective effects of moxifloxacin against Candida albicans-induced bronchopneumonia in mice injected with cyclophosphamide. Antimicrob. Agents Chemother. 46:2442-2449.
Shen, L. L., J. Baranowski, J. Fostel, D. A. Montgomery, and P. A. Lartey. 1992. DNA topoisomerases from pathogenic fungi: targets for the discovery of antifungal drugs. Antimicrob. Agents Chemother. 36:2778-2784.
Shen, L. L., and J. M. Fostel. 1994. DNA topoisomerase inhibitors as antifungal agents. Adv. Pharmacol. 29B:227-244.
Sugar, A. M., X. P. Liu, and R. J. Chen. 1997. Effectiveness of quinolone antibiotics in modulating the effects of antifungal drugs. Antimicrob. Agents Chemother. 41:2518-2521.
Tallarida, R. J. 2006. An overview of drug combination analysis with isobolograms. J. Pharmacol. Exp. Ther. 319:1-7.
Tallarida, R. J. 1992. Statistical analysis of drug combinations for synergism. Pain 49:93-97.
Tallarida, R. J., H. L. Kimmel, and S. G. Holtzman. 1997. Theory and statistics of detecting synergism between two active drugs: cocaine and buprenorphine. Psychopharmacology (Berlin) 133:378-382.
Van Bambeke, F., J. M. Michot, J. Van Eldere, and P. M. Tulkens. 2005. Quinolones in 2005: an update. Clin. Microbiol. Infect. 11:256-280. (Erratum, 11:513.)
Walsh, T. J., and A. H. Groll. 1999. Emerging fungal pathogens: evolving challenges to immunocompromised patients for the twenty-first century. Transpl. Infect. Dis. 1:247-261.
White, T. C., K. A. Marr, and R. A. Bowden. 1998. Clinical, cellular, and molecular factors that contribute to antifungal drug resistance. Clin. Microbiol. Rev. 11:382-402.
Wiederhold, N. P., V. H. Tarn, J. Chi, R. A. Prince, D. P. Kontoyiannis, and R. E. Lewis. 2006. Pharmacodynamic activity of amphotericin B deoxycholate is associated with peak plasma concentrations in a neutropenic murine model of invasive pulmonary aspergillosis. Antimicrob. Agents Chemother. 50:469-473.
